Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. Show more
Location: 1065 East Hillsdale Boulevard, Foster City, CA, 94404, United States | Website: https://www.ternspharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
428M
52 Wk Range
$1.86 - $11.40
Previous Close
$4.87
Open
$4.82
Volume
720,991
Day Range
$4.66 - $4.96
Enterprise Value
-7.259M
Cash
334.3M
Avg Qtr Burn
-17.91M
Insider Ownership
0.28%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 2 Data readout | ||
TERN-501 (THR-B Agonist) +/- TERN-101 (FXR agonist) Details Non-alcoholic steatohepatitis | Phase 2a Update | |
TERN-701 (Allosteric BCR-ABL inhib) Details Chronic myeloid leukemia (CML) | Phase 1 Data readout | |
TERN-101 (FXR agonist) Details Non-alcoholic steatohepatitis | Failed Discontinued | |
TERN-201 (VAP-1 inhibitor) Details Non-alcoholic steatohepatitis | Failed Discontinued |